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Abstract 19 
The release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from bovine milk protein 20 
isolate (MPI) during trypsin hydrolysis was studied using a design of experiments (DOE) 21 
approach. A 3 factor3 level DOE including temperature (40, 50 and 60°C), enzyme to substrate 22 
ratio (E:S; 0.50, 1.25 and 2.00% (w/w)) and hydrolysis time (60, 150 and 240 min) was used 23 
during the generation of 15 hydrolysates (H1-H15). The degree of hydrolysis (DH) varied 24 
between 6.98 ± 0.31 (H8) to 12.75 ± 0.62% (H10). The DPP-IV half maximal inhibitory 25 
concentration (IC50) ranged from 0.68 ± 0.06 (H11)/0.68 ± 0.10 (H4) to 1.59 ± 0.11 mg mL
-1
 26 
(H8). Temperature had no effect (p > 0.05) on the DPP-IV IC50 value, while an increase in E:S or 27 
time significantly decreased DPP-IV IC50 value (p < 0.05). The DPP-IV IC50 value of 0.69 mg 28 
mL
-1
, predicted by response surface methodology (RSM), to be obtained with an hydrolysate 29 
generated at 50.5°C, 2% ES and 231 min (H16) was similar to the experimentally obtained value 30 
(DPP-IV IC50 = 0.66  0.10 mg mL
-1
, p > 0.05, n=3). Following simulated gastrointestinal 31 
digestion (SGID) of H16 (H16_CorPP), the DPP-IV IC50 value increased (p < 0.05) to 0.90 ± 32 
0.07 mg mL
-1
. There was no significant difference between the DPP-IV IC50 value of the SGID of 33 
MPI (MPI_CorPP, 0.89  0.11 mg mL-1) and that of H16_CorPP. Potent known DPP-IV 34 
inhibitory peptide sequences were identified by liquid chromatography-tandem mass 35 
spectrometry (LC-MS/MS) within H16, some of which were also present within H16_CorPP. 36 
MPI hydrolysates may be of interest for serum glucose regulation in humans. 37 
 38 
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1 Introduction 43 
Intact and hydrolysed milk proteins appear quite promising as antidiabetic agents for humans (for 44 
reviews, see: Lacroix & Li-Chan, 2014b; Nongonierma & FitzGerald, 2015b). However, the 45 
mechanisms of action explaining their antidiabetic effects are, to date, not fully understood. 46 
These may involve insulinotropic effects, inhibition of metabolic enzymes or incretin 47 
secretagogue effects (Nongonierma & FitzGerald, 2015a). Dipeptidyl peptidase IV (DPP-IV) is a 48 
metabolic enzyme which plays a role in serum glucose regulation in humans. During the post-49 
prandial phase, DPP-IV can cleave incretins including glucagon-like peptide-1 (GLP-1) and 50 
glucose inhibitory polypeptide (GIP). Incretin degradation causes a loss in their ability to enhance 51 
insulin secretion (insulinotropic action), resulting in a dysregulation in serum glucose level 52 
(Drucker, 2006; Juillerat-Jeanneret, 2014). DPP-IV inhibition is used as a target for antidiabetic 53 
drugs (i.e., gliptins). Interestingly, there is growing evidence showing that certain food protein-54 
derived peptides also have the ability to inhibit DPP-IV (for reviews, see: Jao et al., 2015; 55 
Lacroix & Li-Chan, 2016; Nongonierma & FitzGerald, 2016b) 56 
To date, most studies describing the enzymatic generation of DPP-IV inhibitory hydrolysates 57 
appear to have been carried out with either casein (CN) or whey protein substrates (Lacroix & Li-58 
Chan, 2016). Previous studies have suggested that peptide mixtures may have additive or 59 
antagonistic effects on DPP-IV inhibition (Nongonierma & FitzGerald, 2015c). Utilisation of 60 
substrates containing both CNs and whey proteins may therefore allow a better understanding of 61 
the overall DPP-IV inhibitory effects of bovine milk protein hydrolysates. In this context, milk 62 
protein isolate (MPI), a commercially available protein enriched substrate from bovine milk, was 63 
studied herein. Bovine MPI contains ~90% (w/w) protein with the same CN and whey protein 64 
ratio as in bovine milk (i.e., 80 and 20% (w/w), respectively). In addition, MPI contains low 65 
levels of fat and lactose, which make it very attractive for a wide range of nutritional applications 66 
(for review, see: Agarwal, Beausire, Patel, & Patel, 2015). 67 
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The bioactive potency of food protein hydrolysates, in the context of enzyme inhibition, is often 68 
estimated by their half maximal inhibitory concentration (IC50). Most milk protein hydrolysates 69 
reported in the literature, to date, appear to display IC50 values  1.5 mg mL
-1 
(Lacroix & Li-70 
Chan, 2016). An increased need has been recently placed on the development of milk protein 71 
hydrolysates with enhanced bioactive potency in order to comply with the requirement for 72 
ingestion of physiologically relevant amounts as recommended by regulatory agencies such as the 73 
European Food Safety Authority (EFSA). Higher bioactive potency may be achieved by 74 
increasing the release of potent bioactive peptides during enzymatic hydrolysis. Several factors, 75 
which may be classified as intrinsic (i.e., protein type and concentration, enzyme preparation and 76 
concentration, solvent, pH, ionic strength, etc.) or extrinsic (i.e., temperature, pressure, etc.), are 77 
known to modify the release of bioactive peptides during the enzymatic hydrolysis of food 78 
proteins. This may, in certain instances, be linked with modification of enzyme selectivity for 79 
peptide bond cleavage, e.g., as a function of pH or substrate concentration (Butré, Sforza, 80 
Gruppen, & Wierenga, 2014; Butré, Sforza, Wierenga, & Gruppen, 2015). An efficient manner to 81 
optimise the generation of potent bioactive hydrolysates may be through the utilisation of 82 
multifactorial design of experiments (DOE) followed by prediction of optimum hydrolysis 83 
parameters with response surface methodology (RSM) (Contreras, Hernández-Ledesma, Amigo, 84 
Martín-Álvarez, & Recio, 2011; Nongonierma, Le Maux, Esteveny, & FitzGerald, 2017; van der 85 
Ven, Gruppen, de Bont, & Voragen, 2002).  86 
The aim of this study was to evaluate the role of different parameters on the DPP-IV inhibitory 87 
properties of MPI hydrolysed with trypsin. A three factor (temperature, time and enzyme to 88 
substrate (E:S) ratio)  three level DOE was used herein. Physicochemical characteristics (degree 89 
of hydrolysis (DH), peptide profile and molecular mass distribution) of the hydrolysates were 90 
determined. The model used to develop the RSM was verified by selecting hydrolytic parameters 91 
(i.e., temperature, time and E:S) yielding low DPP-IV half maximal inhibitory concentration 92 
(IC50) within the boundaries of the DOE. The most promising hydrolysate was subjected to an in 93 
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vitro simulated gastrointestinal digestion (SGID) protocol to assess the effect of digestive 94 
enzymes on DPP-IV inhibitory properties. Liquid chromatography-tandem mass spectrometry 95 
(LC-MS/MS) was used to identify the peptides within selected hydrolysates. 96 
2 Materials and methods 97 
2.1 Reagents 98 
2,4,6-Trinitrobenzenesulfonic acid (TNBS) from Pierce Biotechnology was obtained from 99 
Medical Supply Company (Dublin, Ireland). Hydrochloric acid (HCl), sodium hydroxide 100 
(NaOH), high performance liquid chromatography (HPLC) grade water and acetonitrile (ACN) 101 
were from VWR (Dublin, Ireland). Trifluoroacetic acid (TFA), 102 
tris(hydroxymethyl)aminomethane (TRIS), sodium phosphate monobasic, sodium phosphate 103 
dibasic, sodium dodecyl sulfate (SDS), Gly-Pro-pNA, Leu, diprotin A (Ile-Pro-Ile), porcine DPP-104 
IV (≥ 10 units mg-1 protein), standards for molecular mass distribution (i.e., bovine serum 105 
albumin (BSA), β-lactoglobulin (β-Lg), -lactalbumin (-La), aprotinin, bacitracin, Leu-Trp-106 
Met-Arg, Asp-Glu and Tyr), mass spectrometry (MS) grade water and ACN were purchased from 107 
Sigma Aldrich (Dublin, Ireland). Synthetic peptides (purity  95%) for MS studies were 108 
purchased from Bachem (Bubendorf, Switzerland, Ala-Leu, Trp-Tyr, Trp-Lys, Tyr-Leu, Tyr-Ile 109 
and Val-Leu), Thermo Fisher Scientific (Ulm, Germany, Trp-Gln, Leu-Leu, Ile-Leu, Leu-Ile, Ile-110 
Ile and Leu-Pro-Leu) and Sigma-Aldrich (Phe-Leu). MPI (86% (w/w) protein) was obtained from 111 
Kerry Ingredients (Listowel, Ireland). Trypsin was provided by Novozymes (PTN 6.0S, 112 
Bagsvaerd, Denmark), pepsin by Biocatalysts (Cefn, Wales, UK) and Corolase PP (CorPP) by 113 
AB enzymes (Darmstadt, Germany). 114 
2.2 Tryptic hydrolysis of MPI 115 
Three parameters, i.e., temperature, E:S and hydrolysis time, which have been shown to affect 116 
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bioactive peptide release during enzymatic hydrolysis of milk proteins (Contreras et al., 2011; 117 
van der Ven et al., 2002), were selected. The temperature range studied corresponded to the 118 
optimum range for trypsin while hydrolysis time and E:S ratios were selected based on previous 119 
studies (Nongonierma & FitzGerald, 2012). MPI was hydrolysed with trypsin using a DOE 120 
incorporating the parameters incubation temperature (40, 50 and 60°C), E:S (0.50, 1.25 and 121 
2.00% (w/w)) and hydrolysis time (60, 150 and 240 min) which were evaluated at three (-1, 0 and 122 
+1, respectively) different levels (Table 1). Fourteen hydrolysates (H1-H14) were generated once 123 
within the DOE. In addition, the central point (H15, 50C, 1.25% E:S and 150 min) conditions 124 
were used to generate three independent MPI hydrolysates (n=3, H15A, H15B and H15C) to 125 
verify reproducibility of the hydrolytic reaction. 126 
MPI hydrolysis was conducted as described earlier (Nongonierma et al., 2017). Briefly, MPI 127 
(10% (w protein equivalent/w)) was resuspended in distilled water and incubated for 60 min in a 128 
water bath (Lauda E100, Lauda Brinkmann, Lauda-Königshofen, Germany) set at 50C. The pH 129 
was then adjusted to 7.0 with 2 M NaOH. Temperature, E:S and hydrolysis time were set as 130 
defined by the DOE. At the end of each reaction, the enzyme was heat inactivated (90°C, 20 min) 131 
in a water bath. A control sample (unhydrolysed MPI) without enzyme addition was prepared for 132 
each hydrolysis temperature and time. 133 
Hydrolysis conditions yielding the generation of the MPI hydrolysate having low DPP-IV IC50 134 
value within the boundaries of the DOE were predicted by RSM (section 2.3.). The 135 
corresponding MPI hydrolysate was generated in three independent replicates (H16A, H16B and 136 
H16C) to externally validate the predictive model and the reproducibility of the hydrolytic 137 
reaction process. 138 
All samples were freeze-dried (FreeZone 18L, Labconco, Kansas City, MO, USA) and stored at -139 
20°C until utilisation. 140 
2.3 RSM for the prediction of DPP-IV IC50 as a function of hydrolysis parameters of MPI 141 
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The RSM curves were generated within the boundaries of the DOE with a multilinear regression 142 
(MLR) model (Equation 1, complete model) developed using Matlab (version R2015b, 143 
MathWorks, Inc, Natick, MA, USA) as previously described (Nongonierma et al., 2017). 144 
𝑌 = 𝛽0 + 𝛽1𝑇 + 𝛽2𝐸𝑆 + 𝛽3𝑡 + 𝛽4𝑇
2 + 𝛽5𝐸𝑆
2 + 𝛽6𝑡
2 +  𝛽7 𝑇 × 𝐸𝑆 +  𝛽8𝑇 ×  𝑡 + 𝛽9𝐸𝑆 ×  𝑡 +  𝜀    (Equation 1) 145 
 146 
With Y, the DPP-IV IC50 value; β0 to β9: the coefficients of the MLR model; T (temperature), E:S 147 
(enzyme to substrate ratio) and t (time): the centred and reduced (z-centred) parameters of the 148 
experimental design and ε: the residual of the model. 149 
 150 
The complete model (Equation 1) was simplified (simplified model) by taking into account the 151 
main parameters (T, ES and t) and their interactions having a p-value < 0.1 (Contreras et al., 152 
2011). The RSM curves were determined within the boundaries of the DOE. Subsequently, 153 
hydrolysis parameters yielding low DPP-IV IC50 values were determined (Nongonierma & 154 
FitzGerald, 2016a; van der Ven et al., 2002). 155 
2.4 In vitro SGID of intact and hydrolysed MPI 156 
In vitro SGID was conducted with unhydrolysed MPI and H16 as outlined in Walsh et al. (2004). 157 
Briefly, samples were resuspended in distilled water to 2% (w protein equivalent /w) for 30 min 158 
at 37°C and the pH was adjusted to 2.0 using 1 N HCl. Hydrolysis with pepsin (E:S 2.5% (w/w)) 159 
was carried out under pH regulation (2.0) with HCl (pH stat Titrando 843, Tiamo 1.4 Metrohm, 160 
Dublin, Ireland) for 90 min at 37°C. Pepsin was then heat inactivated (90°C, 20 min). An aliquot 161 
of the peptic hydrolysate (MPI_pepsin or H16_pepsin) was brought to pH 7.5 using 1 M NaOH 162 
and then hydrolysed with CorPP (E:S 1% (w/w)) for 150 min at 37°C, pH 7.5 using a pH stat 163 
(Metrohm), to yield MPI_CorPP or H16_ CorPP. The reaction was terminated by thermal 164 
treatment (90°C, 20 min). Samples were freeze-dried and stored at -20°C until utilisation. 165 
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2.5 DPP-IV inhibition assay 166 
The DPP-IV inhibition assay was carried out in triplicate as outlined by Nongonierma and 167 
FitzGerald (2013a). The freeze-dried samples were dispersed in HPLC grade water at 168 
concentrations ranging from 1.1 × 10
-2
 to 2.7 mg mL
-1
 (final concentration expressed in mg 169 
protein equivalent mL
-1
). Diprotin A, a well-known DPP-IV inhibitor, was used as a positive 170 
control at final concentrations ranging from 12.5 × 10
-2
 and 12.5 µg mL
-1
. Essentially, 25L 171 
sample was pipetted in a 96 well clear microplate (Sarstedt, Dublin, Ireland) containing the 172 
reaction substrate, Gly-Pro-pNA (final concentration 0.200 mM). The reaction was initiated by 173 
the addition of DPP-IV (final concentration 0.0025 units mL
-1
). All reagents were diluted in 100 174 
mM Tris-HCl buffer pH 8.0. The negative control consisted of 100 mM Tris-HCl buffer pH 8.0 175 
and Gly-Pro-pNA. The microplate was incubated at 37C for 60 min in a microplate reader 176 
(Biotek Synergy HT, Winoosky, VT, USA). Absorbance of the pNA released from the substrate 177 
by DPP-IV was monitored at 405 nm. The DPP-IV IC50 values were determined by plotting the 178 
percentage inhibition as a function of the test compound concentration. Each analysis was 179 
conducted in triplicate (n=3). 180 
2.6 DH determination 181 
The DH of the hydrolysates (H1-H16) was determined in triplicate (n=3) using the TNBS method 182 
as per Le Maux, Nongonierma, Barre, and FitzGerald (2016). Absorbance values (350 nm) were 183 
measured with a microplate reader (Biotek Synergy HT). DH was calculated using Equation 2: 184 
DH = 100 ×
(AN2−AN1)
N𝑝𝑏 
        (Equation 2) 185 
 186 
With AN1, the amino nitrogen content of the unhydrolysed protein (mg g
-1
 protein); AN2, the 187 
amino nitrogen content of the hydrolysate (mg g
-1
 protein) and Npb, the nitrogen content of the 188 
peptide bonds in the protein substrate (114.34 for MPI). 189 
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2.7 Peptide profile of the hydrolysates by reverse-phase ultra-performance liquid 190 
chromatography (RP-UPLC) 191 
Peptide profiles were determined by RP-UPLC (UPLC Acquity - Waters, Milford, MA, USA) as 192 
described previously (Nongonierma & FitzGerald, 2012). Briefly, samples were resuspended 193 
(0.4% w protein equivalent/v) in solvent A (0.1% (v/v) TFA in MS grade water) and filtered with 194 
a 0.2 µm cellulose acetate filters (VWR). Peptide separation was carried out at 30°C with a flow 195 
rate of 0.3 mL min
-1
 and an injection volume of 10 µL. An Acquity UPLC BEH C18, 130 Å 196 
column (2.1 mm  50 mm  1.7 µm) equipped with an Acquity BEH C18 (1.7 µm) vanguard pre-197 
column, both from Waters, were used. Peptides and proteins were eluted using a linear gradient: 198 
0-0.28 min: 100% A; 0.28-60 min: 100-40% A, with solvent B consisting of 0.1 % (v/v) TFA and 199 
80% MS grade ACN in water. Absorbance was monitored at 214 nm. 200 
2.8 Molecular mass distribution of the hydrolysates by gel permeation high performance 201 
liquid chromatography (GP-HPLC) 202 
The MPI hydrolysates were analysed by GP-HPLC as described earlier (Spellman, O’Cuinn, & 203 
FitzGerald, 2009). An HPLC system (Waters model 600 binary pump, model 2707 autosampler 204 
and model 2489 dual λ absorbance detector interfaced with Empower™) was employed to 205 
analyse samples. Separation of compounds was conducted in isocratic mode at 21°C using a TSK 206 
G2000 SW separating column (600×7.5 mm ID - Tosoh Bioscience, Tokyo, Japan) connected to 207 
a TSKGEL SW guard column (75×7.5 mm ID - Tosoh Bioscience) with a mobile phase made of 208 
0.1% (v/v) TFA and 30% HPLC grade ACN in HPLC water. The flow rate was of 0.5 mL min
-1
 209 
for 60 min. A volume of 20 µL sample (0.22% (w protein equivalent/v) in mobile phase filtered 210 
through 0.2 µm PTFE syringe filters (VWR)) was injected. The absorbance was monitored at 214 211 
nm. The molecular mass standards consisted of BSA, β-Lg, -La, aprotinin, bacitracin, Leu-Trp-212 
Met-Arg, Asp-Glu and Tyr. Molecular mass distribution of compounds > 10, 10-5, 5-1 and < 1 213 
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kDa was determined. 214 
2.9 Peptide identification by liquid chromatography tandem mass spectrometry (LC-215 
MS/MS) 216 
Peptide identification in H4, H11, H16 and the SGID of H16 (H16_CorPP) and MPI 217 
(MPI_CorPP) was carried out by LC-MS/MS. An Acquity UPLC (Waters) fitted with an Acquity 218 
BEH amide 300 C18 column (2.150 mm, 1.7 μm, Waters) was used. The UPLC was coupled to 219 
a quadrupole time-of-flight mass spectrometer (Q-TOF, Impact HD™, Bruker Daltonics GmbH, 220 
Bremen, Germany) using a 50-600 and 50-2500 m/z acquisition range as described earlier 221 
(Norris, Poyarkov, O’Keeffe, & FitzGerald, 2014; O’Keeffe & FitzGerald, 2015). The MS was 222 
fitted with an electrospray ionisation (ESI) source used in positive ion mode. Data acquisition 223 
was performed with Hystar software (Bruker Daltonics). Samples were resuspended in mobile 224 
phase A (0.1% formic acid in MS water) to a final concentration of 0.1 g L
-1
. A sample volume of 225 
2 µL was injected. Peptide identification was carried out with PEAKS Studio (version 7.5, 226 
Bioinformatics Solutions Inc, Waterloo, Canada). The false discovery rate (FDR), average local 227 
confidence (ALC) and MS/MS tolerance were set at 1, 60% and 0.1 Da respectively. In addition, 228 
synthetic peptides (Ala-Leu, Phe-Leu, Leu-Leu/Ile-Leu/Leu-Ile/Ile-Ile, Leu-Pro-Leu, Val-Leu, 229 
Trp-Gln, Trp-Lys, Trp-Tyr, Tyr-Leu/Tyr-Ile) were used to spike hydrolysate samples, which 230 
were subsequently analysed using the same LC-MS/MS conditions in order to confirm the 231 
software identification (data not shown). All other amino acid sequences generated by PEAKS 232 
Studio software were manually checked in order to (1) verify that the peptide sequence 233 
corresponded with the same amino acid sequence in the main milk proteins and (2) control the 234 
peptides fragmentation data as ion series continuity and major peaks identified as b or y ions. 235 
Previously identified DPP-IV inhibitory peptides within the samples were then determined. In 236 
addition, features of known DPP-IV inhibitory peptides reported in the literature, which consist in 237 
an hydrophobic amino acid (Trp, Leu, Ile or Phe) at the N-terminus and/or a Pro/Ala at position 238 
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2, and/or Pro at the C-terminus (Nongonierma & FitzGerald, 2013b, 2014a; Nongonierma & 239 
FitzGerald, 2016a; Tulipano, Faggi, Nardone, Cocchi, & Caroli, 2015) were searched for within 240 
the peptides identified. 241 
2.10 Statistical analysis  242 
Differences between mean DH and DPP-IV IC50 values were analysed with a one-way analysis of 243 
variance (ANOVA) at a significance level p < 0.05. Multiple means comparison (p < 0.05) was 244 
conducted using a post-hoc Student Newman Keuls test with SPSS (version 22, SPSS Inc., 245 
Chicago, IL, USA). The lack of significant difference between the experimentally determined and 246 
predicted DPP-IV IC50 values of H16 was assessed with Matlab using a one-sample Student test 247 
(t-test) with a significance of p < 0.05. 248 
3 Results and Discussion 249 
3.1 Physicochemical and DPP-IV inhibitory properties of the MPI hydrolysates (H1-H15) 250 
generated within the DOE  251 
The molecular mass distribution profiles (Fig. 1) of the hydrolysates H1-H15 showed the 252 
presence of components > 10 kDa, corresponding to unhydrolysed proteins. However, in all 253 
hydrolysates the largest proportion (70 > %) of material was < 5 kDa, showing that most intact 254 
proteins were degraded during the hydrolytic reaction. This was also illustrated by the differences 255 
in peptide profiles between the intact and hydrolysed MPI (Fig. 2A). In the hydrolysates (H4 and 256 
H11), the peaks corresponding to intact proteins seen in the MPI RP-UPLC profile were only 257 
present at low intensity. Hydrolysates contained numerous peptide peaks eluting throughout the 258 
chromatogram. When comparing two hydrolysates (H4 and H11) having the same DPP-IV 259 
inhibitory properties (Table 1), minor differences in terms of occurrence and intensity of peptide 260 
peaks were seen on the RP-profiles (Fig. 2A). The DH of the MPI hydrolysates generated within 261 
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the DOE is reported is Table 1. Hydrolysate generation was reproducible from a DH perspective 262 
as indicated by the values obtained for the triplicate central point hydrolysates (H15A, H15B and 263 
H15C) which were not significantly different (p > 0.05). The DH values of the 15 hydrolysates 264 
generated within the DOE ranged between 6.98  0.31 (H8) and 12.75  0.62% (H10). These 265 
values were of the same order as whey protein hydrolysates generated with PTN6.0S using 266 
similar hydrolytic conditions (Pouliot, Wijers, Gauthier, & Nadeau, 1999).  267 
Similarly to the DH, no significant differences (p > 0.05, Table 1) were found for the DPP-IV 268 
IC50 values of H15A, H15B and H15C. Differences were seen in the DPP-IV IC50 values of the 15 269 
hydrolysates generated within the DOE (Table 1). The highest DPP-IV IC50 value was found with 270 
H8 (1.59  0.11 mg mL-1) while the lowest was seen with both H4 (0.68  0.10 mg mL-1) and 271 
H11 (0.68  0.06 mg mL-1). The relatively high DPP-IV inhibitory potency of H4 and H11 may 272 
be linked with the high E:S (2 %) and the long hydrolysis time ( 150 min) used during their 273 
generation, which resulted in DH values > 11% (Table 1). Milk proteins are currently the most 274 
commonly used substrate for the generation of hydrolysates having DPP-IV inhibitory properties 275 
(Nongonierma & FitzGerald, 2016b). In silico analyses of individual milk proteins predicted that 276 
both CNs and whey proteins contain relatively potent DPP-IV inhibitory peptides (Lacroix & Li-277 
Chan, 2012; Nongonierma & FitzGerald, 2014a). To date, it appears that hydrolysates generated 278 
from substrates containing both CNs and whey proteins have not been extensively investigated 279 
for their ability to inhibit DPP-IV. Therefore, bovine MPI, a protein rich-substrate containing 280 
both CNs and whey proteins, was hydrolysed with trypsin herein. The range of DPP-IV IC50 281 
values (0.62 ± 0.11 to 1.59 ± 0.11 mg mL
-1
, Table 1) obtained with the MPI hydrolysates herein 282 
was of the same order as that of tryptic whey (1.00 mg mL
-1
) or CN (1.11 mg mL
-1
)-based 283 
hydrolysates (Nongonierma & FitzGerald, 2013a).  284 
The complete and simplified MLR models both gave a good fit of the experimental DPP-IV IC50 285 
values as indicated by the non-significant lack of fit (p > 0.05, Table 2). Two parameters of the 286 
DOE (E:S and t) had an effect on the DPP-IV IC50 value (p < 0.05, Table 2), while T had no 287 
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significant effect (p > 0.05). The significance of t
2
 (p < 0.05), was linked with the existence of an 288 
optimum time within the DOE boundaries. Both coefficients associated with E:S and t were 289 
negative, indicating that an increase in E:S or t would result in a reduction in DPP-IV IC50 value. 290 
The complete model gave a better correlation between the experimental and predicted DPP-IV 291 
IC50 values (Table 2 and Supplementary Fig. S1). Therefore, the complete model was employed 292 
to build the RSM curves. The RSM curves showed a lower DPP-IV IC50 value when either E:S or 293 
t were at the +1 (2.00 % E:S and 240 min) vs the -1 (0.50 % and 60 min) level (Fig. 3A, 3B and 294 
3C). In contrast, the temperature value minimally affected the DPP-IV IC50 value (Fig. 3A and 295 
3B). Both E:S and time can affect the kinetics of peptide bond cleavage and therefore modify 296 
peptide release during enzymatic hydrolysis (Contreras et al., 2011). While the extent of -Lg 297 
hydrolysis by trypsin has been shown in earlier studies to be temperature dependant (Cheison, 298 
Schmitt, Leeb, Letzel, & Kulozik, 2010; Iametti et al., 2002), no temperature effect could be 299 
observed in this study. The lack of a temperature effect may arise from the fact that the 300 
temperature range studied was within the optimum range for this trypsin preparation.  301 
3.2 Physicochemical characteristics and DPP-IV inhibitory properties of the MPI 302 
hydrolysate (H16) predicted by RSM to yield low DPP-IV IC50 values 303 
Hydrolysis conditions predicted to yield DPP-IV IC50 values < 0.7 mg mL
-1
 (low DPP-IV IC50 304 
value range Supplementary Fig S2) were selected within the boundaries of the DOE as 50.5C (T 305 
= +0.05), 231 min (t = +0.90) and 2% E:S (+1.00). These conditions were used to externally 306 
validate the predictive model. The complete and simplified models predicted that this hydrolysate 307 
(H16) would yield a DPP-IV IC50 value of 0.69 and 0.68 mg mL
-1
, respectively.  308 
The corresponding hydrolysates (H16A, H16B and H16C) had a similar DH (mean value of 309 
12.96  1.51%, p > 0.05, Table 1). All three hydrolysates, which contained > 90% material < 5 310 
kDa, displayed similar molecular mass distribution profiles (Fig. 1). The DPP-IV IC50 values of 311 
H16A, H16B and H16C were not significantly different (p > 0.05, Table 1). The experimentally 312 
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determined (mean value of 0.66  0.10 mg mL-1) and predicted (0.69/0.68 mg mL-1) DPP-IV IC50 313 
values for H16 were not significantly different (Student test, p > 0.05). These results validated the 314 
models developed herein. While the RSM approach has some benefits for predicting optimum 315 
hydrolysis parameters during the generation of bioactive peptides (van der Ven et al., 2002), 316 
some limitations exists. Notably, the substrate may become limiting during the course of 317 
hydrolysis as may be suggested by the low level of variation in the DPP-IV IC50 values (between 318 
0.60 and 0.8 mg mL
-1
) for a number of hydrolysates generated with different hydrolysis 319 
parameters (Table 1 and Supplementary Fig. S2A and S2B). Furthermore, inhibition of trypsin by 320 
peptides released during hydrolytic reactions may also occur (Iametti et al., 2002). 321 
3.3 DPP-IV inhibitory properties of H16B and MPI following SGID 322 
Hydrolysate H16B was subjected to the SGID protocol. Hydrolysates H16B before and after 323 
pepsin digestion (H16B_pepsin) had similar molecular mass distribution (Fig. 1) as well as 324 
peptide profiles (Fig. 2B). The pepsin and CorPP digest (H16B_CorPP) had a different molecular 325 
mass distribution (Fig. 1) from H16B, showing > 99% of the material present within 326 
H16B_CorPP being < 5 kDa vs. ~ 94% in H16B. Differences were also seen in the RP-UPLC 327 
peptide profiles of H16B and H16B_CorPP (Fig. 2B), notably in terms of peptide peaks eluting 328 
before 10 and after 15 min. Following SGID of MPI, major differences were seen in the 329 
molecular mass distribution, indicating significant protein breakdown in the MPI both after 330 
pepsin (MPI_pepsin) and CorPP (MPI_CorPP) digestion (Fig. 1). The MPI proteins were also 331 
degraded in MPI_pepsin and MPI_CorPP as indicated by the RP-profiles (Fig. 2C). 332 
A significant increase in the DPP-IV IC50 value of H16B (0.62  0.11 mg mL
-1
) was seen in 333 
H16B_pepsin and H16B_CorPP (0.87  0.05 and 0.90  0.07 mg mL-1, respectively, p < 0.05, 334 
Table 1). In contrast, the DPP-IV IC50 value of MPI (> 2.7 mg mL
-1
) was decreased in 335 
MPI_pepsin (2.74  0.53 mg mL-1) and MPI_CorPP (0.89  0.11 mg mL-1, Table 1). No 336 
significant differences (p > 0.05, Table 1) were seen between the DPP-IV IC50 values of 337 
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MPI_CorPP and H16B_CorPP. Pepsin cleaves proteins and peptides at the C-terminal side of 338 
hydrophobic amino acids such as Phe and Leu (Godfrey, 1996). CorPP contains several enzyme 339 
activities including trypsin, chymotrypsin, elastase and a range of exopeptidases (Mullally, 340 
O'Callaghan, FitzGerald, Donnelly, & Dalton, 1994). Trypsin, chymotrypsin and elastase are 341 
mammalian intestinal endoproteinases which preferentially cleave peptide bonds at the C-342 
terminal side of Arg/Lys, bulky hydrophobic amino acids such as Tyr/Trp/Phe/Lys or 343 
Leu/Ala/Val/Ile, respectively (Godfrey, 1996). Their cleavage specificity may be affected by 344 
hydrolysis temperature. For instance, Cheison et al. (2010) reported modifications of trypsin 345 
specificity which resembled that of chymotrypsin when the temperature reached 40-45C during 346 
-Lg hydrolysis. This was explained by conformational changes in the active site of trypsin, 347 
which may have allowed a better accessibility for hydrophobic bulky amino acids. The presence 348 
of exopeptidases within CorPP, may have resulted in a further cleavage of peptide bonds within 349 
both H16B_CorPP and MPI_CorPP. This hypothesis is consistent with the fact that the RP-UPLC 350 
peptide profiles of H16B_CorPP (Fig. 2B) and MPI_CorPP (Fig. 2C) are very similar. In 351 
addition, similarities exist between the enzyme activities (i.e., trypsin and chymotrypsin) in PTN 352 
6.0S, the commercial trypsin preparation used during the generation of H16B, and CorPP. In fact 353 
certain peptides released by PTN 6.0S were not further degraded following SGID (Table 3). 354 
3.4 Peptide identification within MPI hydrolysates 355 
Various MPI hydrolysates (e.g., H4, H11 and H16B) displayed the same DPP-IV IC50 value (p > 356 
0.05, Table 1). Despite similarities in their DPP-IV inhibitory potency, some differences in the 357 
presence of known DPP-IV inhibitory peptides within these hydrolysates were seen (Table 3). 358 
Numerous DPP-IV inhibitory peptides were common between the three samples, some of which 359 
were relatively potent, having IC50 values < 100 µM. The most potent peptide identified within 360 
these samples was Ile-Asn-Asn-Gln-Phe-Leu-Pro-Tyr-Pro-Tyr (κ-CN (f51-60)), which had a 361 
reported DPP-IV IC50 value of 40 µM (Zhang, Chen, Ma, & Chen, 2015). All 18 previously 362 
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identified DPP-IV inhibitory peptides present within H4 were also observed within H11 and 363 
H16B. In addition to these 18 DPP-IV inhibitory peptides identified in H4, H16B also contained 364 
a particularly potent DPP-IV inhibitor, Val-Pro-Leu (s1-CN (f167-169)), known as Diprotin B, 365 
having a DPP-IV IC50 value of 15.8 µM (Umezawa et al., 1984), which was not found within H4 366 
or H11. In agreement with trypsin and chymotrypsin specificity, numerous peptides possessing 367 
Arg, Lys, Tyr, Trp and Phe residues at their C-terminus were identified within H4, H11 and 368 
H16B (Table 3 and 4). 369 
In addition to known DPP-IV inhibitory peptides, the hydrolysates contained peptides possessing 370 
the features of DPP-IV inhibitory peptides (i.e., Leu, Ile or Phe at the N-terminus and/or Pro/Ala 371 
at position 2, and/or Pro at the C-terminus). The peptides with the above features identified 372 
within H16B are summarised in Table 4. H16B did not contain peptides with a Trp at the N-373 
terminus. However, peptides possessing one or several of the other features were identified. 374 
While the DPP-IV inhibitory potential of the majority of the peptides reported in Table 4 is 375 
unknown, they may play a role in the overall DPP-IV inhibitory activity of H16B. In particular, 376 
peptides (possessing a Pro or Ala at the penultimate position) which can act as substrates for 377 
DPP-IV are likely to interact with its active site and induce a substrate-type inhibition effect 378 
(Nongonierma & FitzGerald, 2014b). Interestingly, a number of substrate-like peptides, mostly 379 
arising from CNs, were identified within H16B (Table 4). Leu/Ile residues at the N-terminus of 380 
peptides within H16B were also frequently found, arising from either CNs or whey proteins 381 
(Table 4). Hydrophobic amino acids such as Leu, Ile and Phe located at the N-terminal position 382 
of peptides might interact with the hydrophobic pocket found at the active site of DPP-IV (Engel 383 
et al., 2003; Nongonierma, Mooney, Shields, & FitzGerald, 2013), which may explain their DPP-384 
IV inhibitory properties. 385 
All previously identified DPP-IV inhibitory peptides within H16B were also found within 386 
H16B_CorPP (Table 3), with the exception of Ile-Pro-Ala-Val-Phe (-Lg (f78-82)), Ile-Pro-Ala-387 
Val-Phe-Lys (-Lg (f78-83)) and Val-Ala-Gly-Thr-Trp-Tyr (-Lg (f15-20)). H16B_CorPP 388 
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contained one previously identified DPP-IV inhibitory peptide, Leu-Lys-Pro-Thr-Pro-Glu-Gly-389 
Asp-Leu (-Lg (f46-54)), which was not found within H16B. Following SGID of H16B, some of 390 
the known DPP-IV inhibitory peptides (i.e., Ile-Pro-Ala-Val-Phe and Ile-Pro-Ala-Val-Phe-Lys) 391 
appeared to have been degraded by the hydrolytic activity of enzymes present within pepsin or 392 
CorPP preparations. The decrease of DPP-IV inhibitory activity of H16B_CorPP compared to 393 
H16B (Table 1) may indicate that these peptides play an important role in the overall bioactivity 394 
of H16B. 395 
All 17 of the previously identified DPP-IV inhibitory peptides within MPI_CorPP were the same 396 
as those found within H16B_CorPP (Table 3). This may partly explain why both samples had the 397 
same DPP-IV inhibitory potency (Table 1). The benefit of prehydrolysing MPI with PTN 6.0S 398 
could not be demonstrated as H16B_CorPP and MPI_CorPP had the same DPP-IV IC50 value 399 
(Table 1). In vivo evaluation of MPI and H16 is required to demonstrate the significance of the 400 
results reported herein to the potential in vivo DPP-IV inhibitory activity of these hydrolysates. 401 
Promising data is available in the literature which demonstrates that milk protein-derived peptides 402 
displaying DPP-IV inhibitory properties in vitro have antidiabetic effects in small animals (Hsieh 403 
et al., 2016; Uchida, Ohshiba, & Mogami, 2011; Uenishi, Kabuki, Seto, Serizawa, & Nakajima, 404 
2012). In one instance, these antidiabetic effects have directly been linked with a reduction in 405 
plasma DPP-IV activity (Hsieh et al., 2016). 406 
4 Conclusions 407 
The DPP-IV inhibitory properties of MPI hydrolysates generated with trypsin were influenced by 408 
the E:S and incubation time but not by the temperature. Generation of MPI hydrolysates with 409 
relatively low DPP-IV IC50 values was achieved herein. However, the variation in the DPP-IV 410 
IC50 value observed following modification of the hydrolytic parameters (temperature, E:S and 411 
time) were relatively modest. This may be linked to the fact that DPP-IV inhibitory peptides 412 
could not be further released within the hydrolysates, either because of a rate limiting effect of 413 
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the MPI substrate or modification of trypsin activity during the course of hydrolysis. Several 414 
known, potent DPP-IV inhibitory peptides were identified within the MPI hydrolysates, arising 415 
from both CNs and whey proteins. Even though a loss in DPP-IV inhibitory potency was seen in 416 
H16B_CorPP, some of the known DPP-IV inhibitory peptides identified in H16B were stable to 417 
gastrointestinal enzymes. MPI_CorPP had the same DPP-IV inhibitory potency as H16B_CorPP, 418 
which raises the question of the relevance of these findings to the comparative in vivo activity of 419 
H16B and MPI. 420 
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Table 1. Degree of hydrolysis (DH) and dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory 578 
concentration (IC50) of the 15 milk protein isolate (MPI) hydrolysates generated within the experimental 579 
design (H1-H15), the externally validated samples (H16A, H16B and H16C), H16B digested with pepsin 580 
(H16B_pepsin), H16B_pepsin digested with Corolase PP (H16B_CorPP), MPI digested with pepsin 581 
(MPI_pepsin) and MPI digested with Corolase PP (MPI_CorPP). 582 
Hydrolysate Variable levels1 DH2 (%) DPP-IV IC50
2,3 
(mg mL-1) 
Temperature (°C) E:S (%)  Time (min) 
H1 60 0.50 60 7.47  0.31ab 1.37  0.20f 
H2 60 0.50 240 9.30  0.23bc 0.940  0.15cde 
H3 40 0.50 240 9.28  0.08bc 1.02  0.05de 
H4 40 2.0 240 11.27  0.20cde 0.68  0.10abc 
H5 40 2.0 60 9.13  0.08bc 1.12  0.12e 
H6 60 2.0 60 11.30  0.35cde 0.90  0.15bcde 
H7 60 2.0 240 11.45  0.09de 0.87  0.19bcd 
H8 40 0.50 60 6.98  0.31a 1.59  0.11g 
H9 60 1.25 150 10.43  0.13cd 0.81  0.10abcd 
H10 50 1.25 240 12.75  0.62de 0.79  0.13abcd 
H11 50 2.0 150 12.19  0.15de 0.68  0.06abc 
H12 50 1.25 60 9.13  0.20cd 1.00  0.10de 
H13 40 1.25 150 10.76  0.39cd 0.91  0.09cde 
H14 50 0.50 150 9.71  0.31c 0.78  0.11abcd 
H15A 50 1.25 150 10.56  0.25cd 0.83  0.10abcd 
H15B 50 1.25 150 10.86  0.59cd 0.81  0.07abcd 
H15C 50 1.25 150 11.32  0.09cde 0.73  0.15abc 
H16A 50.5 2.0 231 12.62  1.78de 0.64  0.06ab 
H16B 50.5 2.0 231 13.48  1.20e 0.62  0.11a 
H16C 50.5 2.0 231 12.76  1.61de 0.73  0.09abc 
H16_pepsin - - - nd 0.87  0.05bcd 
H16_CorPP - - - nd 0.90  0.07bcde 
MPI_pepsin - - - nd 2.74  0.53h 
MPI_CorPP - - - nd 0.89  0.11bcd 
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1
Parameters incubation temperature (40, 50 and 60°C), E:S (0.50, 1.25 and 2.00% (w/w)) and hydrolysis 583 
time (60, 150 and 240 min) evaluated at three z-centred levels (-1, 0 and +1, respectively). 584 
2
Mean  SD (n=3). Within the same column, values with different superscript letters are significantly 585 
different (p < 0.05). nd: not determined. 586 
3
IC50: concentration inducing 50% DPP-IV inhibition, expressed in mg protein equivalent per mL (mg mL
-
587 
1
). The IC50 value of the positive control, Ile-Pro-Ile, was 2.63 ± 0.34 µM. 588 
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Table 2. Coefficients of the multilinear regression (MLR) model (Equation 2) correlating the dipeptidyl peptidase IV (DPP-IV) inhibition half maximal 589 
concentration (IC50) of the milk protein isolate (MPI) hydrolysates to the parameters of the design of experiments (DOE) and their interactions (complete 590 
model) and to the main parameters of the DOE and interactions having a p-value < 0.1 (simplified model). 591 
 Parameters of the model
1 
Coefficients Estimate value Standard Error t value p
 
Complete model Intercept 𝛽0 0.740 0.040 18.36 3.520E-07 
 T 𝛽1 -0.029 0.030 -0.98 0.358 
 ES 𝛽2 -0.153 0.030 -5.13 0.001 
 t 𝛽3 -0.167 0.030 -5.59 0.001 
 T² 𝛽4 0.072 0.058 1.26 0.249 
 ES² 𝛽5 0.056 0.058 0.97 0.364 
 t² 𝛽6 0.186 0.058 3.23 0.014 
 T×ES  𝛽7 0.020 0.033 0.61 0.560 
 T×t 𝛽8 0.077 0.033 2.31 0.054 
 ES×t 𝛽9 0.051 0.033 1.54 0.168 
 Root mean squared error = 0.0942; R
2
 = 0.935; p-value model = 0.00223; p-value lack of fit = 0.213 
Simplified model Intercept 𝛽0 0.777 0.039 19.68 6.371E-10 
 T 𝛽1 -0.029 0.033 -0.89 0.394 
 ES 𝛽2 -0.153 0.033 -4.63 7.279E-04 
 t 𝛽3 -0.167 0.033 -5.05 3.750E-04 
 t² 𝛽4 0.252 0.051 4.89 4.796E-04 
 T×t 𝛽5 0.077 0.037 2.08 0.061 
 Root mean squared error = 0.104; R
2
 = 0.873; p-value model = 0.000128; p-value lack of fit = 0.196 
1
T: temperature; ES: enzyme to substrate ratio and t: time. 592 
2
Parameters
 
having a p < 0.05 are significantly different from 0. 593 
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Table 3. Peptides identified by liquid chromatography tandem mass spectrometry (LC-MS/MS) within H4, H11, H16 before and after (H16_CorPP) simulated 594 
gastrointestinal digestion (SGID) and milk protein isolate after SGID (MPI_CorPP), which have previously been reported in the literature for their dipeptidyl 595 
peptidase IV (DPP-IV) inhibitory properties. 596 
Peptide 
sequence
1
 
Fragment
2
 Identified in
3
 DPP-IV IC50 
value (µM)
4 
Reference 
H4 H11 H16 H16_CorPP MPI_CorPP   
AL diverse      882 (Nongonierma & FitzGerald, 
2013a) 
FF diverse      547 (Neves, Harnedy, O’Keeffe, & 
FitzGerald, 2017) 
FL diverse      400 (Nongonierma & FitzGerald, 
2013a) 
INNQFLPYPY κ-CN (f51-60)      40 (Zhang et al., 2015) 
IPAVF -Lg (f78-82)    nd nd 44.7 (Silveira, Martínez-Maqueda, 
Recio, & Hernández-Ledesma, 
2013) 
IPAVFK -Lg (f78-83)    nd nd 143 (Silveira et al., 2013) 
LKPTPEGDL -Lg (f46-54) nd nd nd   45 (Lacroix & Li-Chan, 2014a) 
LL diverse      192 (Connolly, O'Keeffe, 
Nongonierma, Piggott, & 
FitzGerald, 2016) 
LPL -CN (f135-137), 
-CN (f137-139) 
     241.4 (Nongonierma & FitzGerald, 
2014b) 
TPEVDDEALEK -Lg (f125-135)      320 (Silveira et al., 2013) 
VAGTWY -Lg (f15-20)    nd nd 174 (Uchida et al., 2011) 
VL diverse      74 (Lan et al., 2015) 
VLDTDY -Lg (f92-99)      471 (Lacroix, Meng, Cheung, & Li-
Chan, 2016) 
VLVLDTDYK -Lg (f92-100)      424 (Silveira et al., 2013) 
VPL s1-CN (f167-169) nd nd    15.8 (Umezawa et al., 1984) 
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VR diverse      826 (Nongonierma & FitzGerald, 
2013a) 
WQ LF (f22-23), κ-CN 
(f76-77) 
     120 (Nongonierma & FitzGerald, 
2013c) 
WY s1-CN (f164-165), 
-Lg (f19-20) 
     281 (Nongonierma & FitzGerald, 
2013a) 
YL diverse      940 (Le Maux, Nongonierma, Murray, 
Kelly, & FitzGerald, 2015) 
YPVEPF -CN (f114-119)      125 (Nongonierma & FitzGerald, 
2016c) 
1
Peptide sequences abbreviated with the one letter amino acid code 597 
2
CN: casein; LF: lactoferrin; -Lg: -lactoglobulin. Diverse: peptide sequences identified more than twice within the major milk proteins. Fragment numbers 598 
are provided for the mature protein sequence. 599 
3: peptide identified within the hydrolysate; nd: not detected. 600 
4
DPP-IV IC50: dipeptidyl peptidase IV half maximal inhibitory concentration as reported on the first mention in the literature. 601 
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Table 4. Peptide sequences identified within H16, which display features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (i.e., Trp (W1), Ile (I1), Leu 602 
(L1) or Phe (F1) at the N-terminus and/or Pro (P2)/Ala (A2) at position 2 and/or Pro at the C-terminus (PC-term)). 603 
Peptide sequence
1
 Fragment
2
 DPP-IV inhibitory peptide features 
 W1 I1 L1 F1 P2 A2 PC-term 
EAM(+15.99)APK -CN (f100-105)        
EAMAPK -CN (f100-105)        
EPM(+15.99)IGVNQELAY s1-CN (f133-144)        
EPM(+15.99)IGVNQELAYF s1-CN (f133-145)        
EPMIGVNQE s1-CN (f133-141)        
EPMIGVNQE(+21.98)LAY s1-CN (f133-144)        
EPMIGVNQEL s1-CN (f133-142)        
EPMIGVNQELA s1-CN (f133-143)        
EPMIGVNQELAY s1-CN (f133-144)        
EPMIGVNQELAYF s1-CN (f133-145)        
FALPQ s2-CN (f174-178)        
FF diverse        
FFSDK κ-CN (f17-21)        
FFVAPFPEVF s1-CN (f23-32)        
FFVAPFPEVFGK s1-CN (f23-34)        
FL diverse        
FQS(+79.97)EEQQQTEDEL -CN (f33-45)        
FQS(+79.97)EEQQQTEDELQDK -CN (f33-48)        
FVAPFPEVF s1-CN (f24-32)        
FVAPFPEVFGK s1-CN (f23-34)        
FY diverse        
FYPELF s1-CN (f145-150)        
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GPFPI -CN (f203-207)        
GPFPII -CN (f203-208)        
GPFPIIV -CN (f203-209)        
GPFPIIV(+21.98) -CN (f203-209)        
HPHPH κ-CN (f98-102)        
IDALNENK -Lg (f84-91)        
IGVNQELAY s1-CN (f136-144)        
IHPFAQ -CN (f49-54)        
IHPFAQTQ -CN (f49-56)        
IIAEK -Lg (f71-75)        
INNQFLPYPY κ-CN (f51-60)        
IPAVF -Lg (f78-82)        
IQKEDVPSERY s1-CN (f81-91)        
ISQET s2-CN (f15-19)        
ITVDDK s2-CN (f71-76)        
L(I)AK diverse        
LAY s1-CN (f144-142)        
LEDS(+79.97)PEVIESPPEINTV κ-CN (f145-162)        
LEEL -CN (f3-6)        
LEIVPN s1-CN (f109-114)        
LEIVPNS(+79.97)AEER s1-CN (f109-119)        
L(I)EK -Lg (f133-135), 
BSA (f289-291) 
       
LEQLLR s1-CN (f95-100)        
L(I)F diverse        
LGYLEQLLR s1-CN (f92-100)        
LHLPLP -CN (f133-138)        
LHSMK s1-CN (f120-124)        
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LIVTQ -Lg (f1-5)        
LIVTQTMK -Lg (f1-8)        
LIVTQTMKGLDIQKVAGTWYSLAMAASDISLLD -Lg (f1-33)        
L(I)K diverse        
L(I)KK diverse        
LL diverse        
LLR diverse         
LLY -CN (f191-193), 
BSA (f159-161) 
       
LLYQEPVLGPVR -CN (f191-202)        
LNENLLR s1-CN (f16-22)        
LNFL s1-CN (f161-164)        
LNFLK s1-CN (f161-165)        
L(I)Q/LGA diverse        
LQSW -CN (f140-143)        
LQSWMHQPHQPLPPTVMFPPQSVL -CN (f140-163)        
LSF -Lg (f149-151), κ-
CN (f103-105) 
       
LSFM κ-CN (f103-106)        
LSFNPT -Lg (f149-154)        
LSFNPTQLEEQ -Lg (f149-159)        
LSQSKVLPVPQK -CN (f165-176)        
LTDVENLHLPLPL -CN (f127-139)        
LTEEEK s2-CN (f153-158)        
LY diverse        
LYQEPVLGPVR -CN (f192-202)        
LYQGPIVLNPWDQVK s2-CN (f99-11)        
M(+15.99)AIPPK κ-CN (f106-111)        
  34 
MAIPPK κ-CN (f106-111)        
NANEEEY s2-CN (f46-52)        
NAVPITPT s2-CN (f115-122)        
NAVPITPTLNR s2-CN (f115-125)        
PAAVR κ-CN (f64-68)        
RPK s1-CN (f1-3)        
S(+79.97)AEER s1-CN (f115-119)        
SPAQILQWQ κ-CN (f69-77)        
SPAQILQWQVL κ-CN (f69-79)        
TPEVDDEALEK -Lg (f125-135)        
TPEVDDEALEKF -Lg (f125-136)        
VAGTWY -Lg (f15-20)        
VAPFPE s1-CN (f25-30)        
VAPFPEVF s1-CN (f25-32)        
VAPFPEVFGK s1-CN (f25-34)        
VPLGTQY s1-CN (f167-173)        
VPQLEIVPN s1-CN (f106-114)        
VPQLEIVPNS(+79.97)AEER s1-CN (f106-119)        
YAKPA κ-CN (f61-65)        
YAKPAAVR κ-CN (f61-68)        
YPELF s1-CN (f146-150)        
YPELFR s1-CN (f146-151)        
YPSY κ-CN (f35-38)        
YPSYGLNY κ-CN (f35-42)        
YPSYGLNYY κ-CN (f35-43)        
YPVEPF -CN (f114-119)        
1
Peptide sequences abbreviated with the one letter amino acid code; Post translational modification: oxidation (+15.99), phosphorylation (+79.97) and sodium 604 
adduct: (+21.98). 605 
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2
BSA : bovine serum albumin ; CN: casein ; LF: lactoferrin, -Lg: -lactoglobulin. Diverse: peptide sequences identified more than twice within the major milk 606 
proteins. Fragment numbers are provided for the mature protein sequence. 607 
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Figure captions 608 
 609 
Figure 1. Molecular mass distribution of (A) the 15 milk protein isolate (MPI) hydrolysates 610 
generated within the experimental design (H1-H15), the samples generated using the 611 
response surface methodology (RSM) prediction (H16A, H16B and H16C), H16B digested 612 
with pepsin (H16B_pepsin), H16B_pepsin digested with Corolase PP (H16B_CorPP), MPI, 613 
MPI digested with pepsin (MPI_pepsin) and MPI_pepsin digested with Corolase PP 614 
(MPI_CorPP). 615 
 616 
Figure 2. Reverse phase ultra-performance liquid chromatography (RP-UPLC) profiles of the 617 
milk protein isolate (MPI) hydrolysates (A) H4, H11 and MPI, (B) H16B, H16B digested 618 
with pepsin (H16B_pepsin) and H16B_pepsin digested with Corolase PP (H16B_CorPP) and 619 
(C) MPI, MPI digested with pepsin (MPI_pepsin) and MPI_pepsin digested with Corolase PP 620 
(MPI_CorPP). ACN: acetonitrile. 621 
 622 
Figure 3. Response surface methodology (RSM) curves of the dipeptidyl peptidase IV (DPP-623 
IV) half maximal concentration (IC50) as a function of (A) temperature (Temp) and enzyme 624 
to substrate ratio (ES), (B) time and Temp and (C) ES and time. The RSM was constructed 625 
using the complete model and at the central condition (0) of the parameter which is not varied 626 
on each figure panel. 627 
 628 
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Supplementary Figure S1. Predicted dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory 
concentration (IC50) obtained with (A) the complete and (B) the simplified models as a function of the 
experimentally (observed) determined DPP-IV IC50 value of hydrolysates H1-H16. H16 is the external 
validation sample. 
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Supplementary Figure S2. (A) Proportion of predicted dipeptidyl peptidase IV (DPP-IV) 1 
half maximal inhibitory concentration (IC50) values within different ranges obtained using the 2 
simplified and the complete models. (B) Predicted DPP-IV IC50 values used to build the RSM 3 
in the simplified and the complete models (predictions are ordered by increasing DPP-IV IC50 4 
value). 5 
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